Cargando…

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

PURPOSE: To evaluate the role of Decitabine in the allo-HSCT conditioning regimen for intermediate- and high-risk patients with MDS or AML. PATIENTS AND METHODS: Retrospective analysis of data pertaining to 76 intermediate- and high-risk patients with MDS or AML who underwent allo-HSCT between Decem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qing Ya, Li, Yuan, Liang, Ze Yin, Yin, Yue, Liu, Wei, Wang, Qian, Dong, Yu Jun, Sun, Yu Hua, Xu, Wei Lin, Ren, Han Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900353/ https://www.ncbi.nlm.nih.gov/pubmed/31824191 http://dx.doi.org/10.2147/CMAR.S229768

Ejemplares similares

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia
por: Zhao, Haitao, et al.
Publicado: (2020)

Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia
por: Liu, Jia, et al.
Publicado: (2021)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
por: Wang, Yuxin, et al.
Publicado: (2022)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
por: Li, Hongjiao, et al.
Publicado: (2020)

A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia
por: Wang, Jingbo, et al.
Publicado: (2018)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes
por: Zhu, Huan, et al.
Publicado: (2021)

Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis
por: Zhang, Donghui, et al.
Publicado: (2022)

Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis
por: Li, Ziying, et al.
Publicado: (2022)

Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Culos, Katie, et al.
Publicado: (2019)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome
por: Wei, Yunxiong, et al.
Publicado: (2021)

Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation Do Not Fit All: Adjusting BuCy2 in Mexico to Improve Outcomes in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
por: León-Rodríguez, Eucario, et al.
Publicado: (2022)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials
por: Song, Yanzhi, et al.
Publicado: (2021)

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
por: Wang, Lu, et al.
Publicado: (2022)

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
por: Negrotto, Soledad, et al.
Publicado: (2011)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
por: Lipof, Jodi J., et al.
Publicado: (2018)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
por: Baron, Frédéric, et al.
Publicado: (2019)

Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies
por: Yanada, Masamitsu, et al.
Publicado: (2022)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study
por: Wang, Ling, et al.
Publicado: (2021)

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation
por: Saberian, Chantal, et al.
Publicado: (2021)

Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients
por: Li, MinMing, et al.
Publicado: (2021)

Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies
por: Li, Dandan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5k4394n83raf75fjk5ogkdhqa4